Market Cap 133.58M
Revenue (ttm) 70.39M
Net Income (ttm) -43.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -62.47%
Debt to Equity Ratio 0.79
Volume 1,823,200
Avg Vol 2,458,954
Day's Range N/A - N/A
Shares Out 90.87M
Stochastic %K 44%
Beta 2.49
Analysts Strong Sell
Price Target $6.58

Company Profile

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with A...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 421 8100
Address:
200 Penobscot Drive, Redwood City, United States
Fingerlickengood
Fingerlickengood Mar. 21 at 4:11 AM
$CDXS Sometimes I wonder if they say things intentionally in their PRs to provide clues to whom they are working with, without directly breaching their contractional duties to not explicitly state it. $NVS "Codexis Inc., a provider of enzymatic solutions for therapeutics manufacturing, has entered into an agreement with an 'innovator pharmaceutical company' to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis .." No go look at Novartis home page, how many times do they use the word 'innovative/innovator/innovation'? https://www.novartis.com/research-and-development
1 · Reply
SnowyDingo
SnowyDingo Mar. 20 at 7:15 PM
$CDXS $QQQ please review this hidden gem
0 · Reply
Fingerlickengood
Fingerlickengood Mar. 20 at 3:49 PM
$CDXS $NVS $RNA And lines up nicely with an 'unnamed company' in their latest PR . "This agreement allows Codexis to supply siRNA material to support its partner’s preclinical program targeting a cardiovascular indication. Successfully delivering 50 grams marks an inflection point—more than tenfold typical research volumes—signaling Codexis’s capability to meet more demanding supply needs as RNA therapies expand into more prevalent diseases." Just saying ;) https://marketchameleon.com/articles/b/2026/3/5/codexis-agreement-50g-sirna-eco-synthesis-platform-expansion
1 · Reply
Fingerlickengood
Fingerlickengood Mar. 20 at 3:46 PM
0 · Reply
peepthestamp
peepthestamp Mar. 20 at 3:43 PM
$CDXS -Aging Well 👀
0 · Reply
Fingerlickengood
Fingerlickengood Mar. 20 at 3:42 PM
$CDXS $NVS $RNA Falls nicely in hand with their latest venture, Atrium Therapeutics and "will focus on precision RNA therapeutics for rare, genetic cardiomyopathies." https://www.pharmavoice.com/news/novartis-avidity-atrium-spinoff-rna-heart/815050/
1 · Reply
10xMoonstocks
10xMoonstocks Mar. 20 at 3:24 PM
$CDXS So much for shorts vacating. There is a ton of shares available currently. Every run has been countered by shorts bringing it back down....Just one contract announcement and they may disappear for a little while
0 · Reply
Michael2006
Michael2006 Mar. 20 at 1:50 PM
0 · Reply
nlstbro
nlstbro Mar. 20 at 1:46 PM
0 · Reply
nlstbro
nlstbro Mar. 20 at 1:46 PM
0 · Reply
Latest News on CDXS
Codexis, Inc. (CDXS) Q4 2025 Earnings Call Transcript

Mar 11, 2026, 7:52 PM EDT - 9 days ago

Codexis, Inc. (CDXS) Q4 2025 Earnings Call Transcript


Codexis Achieves ISO 9001:2015 Certification

Feb 10, 2026, 9:00 AM EST - 5 weeks ago

Codexis Achieves ISO 9001:2015 Certification


Codexis, Inc. (CDXS) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 2:16 PM EST - 4 months ago

Codexis, Inc. (CDXS) Q3 2025 Earnings Call Transcript


Codexis to Participate in Cantor Global Healthcare Conference

Aug 28, 2025, 9:00 AM EDT - 7 months ago

Codexis to Participate in Cantor Global Healthcare Conference


Codexis, Inc. (CDXS) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:57 PM EDT - 7 months ago

Codexis, Inc. (CDXS) Q2 2025 Earnings Call Transcript


Codexis Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 4:05 PM EDT - 7 months ago

Codexis Reports Second Quarter 2025 Financial Results


Codexis to Participate in Jefferies Global Healthcare Conference

May 21, 2025, 4:05 PM EDT - 10 months ago

Codexis to Participate in Jefferies Global Healthcare Conference


Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript

May 14, 2025, 6:50 PM EDT - 11 months ago

Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript


Codexis Reports First Quarter 2025 Financial Results

May 14, 2025, 4:05 PM EDT - 11 months ago

Codexis Reports First Quarter 2025 Financial Results


Codexis to Report First Quarter 2025 Financial Results on May 14

Apr 30, 2025, 4:05 PM EDT - 11 months ago

Codexis to Report First Quarter 2025 Financial Results on May 14


Codexis Announces New Employment Inducement Grants

Mar 7, 2025, 4:05 PM EST - 1 year ago

Codexis Announces New Employment Inducement Grants


Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 10:20 PM EST - 1 year ago

Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript


Codexis Appoints Christos Richards to Board of Directors

Jan 16, 2025, 4:05 PM EST - 1 year ago

Codexis Appoints Christos Richards to Board of Directors


Codexis to Participate in Upcoming Healthcare Conferences

Nov 4, 2024, 4:05 PM EST - 1 year ago

Codexis to Participate in Upcoming Healthcare Conferences


Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 10:48 PM EDT - 1 year ago

Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript


Codexis Publishes FY2023 Sustainability Disclosures

Aug 15, 2024, 4:05 PM EDT - 1 year ago

Codexis Publishes FY2023 Sustainability Disclosures


Codexis, Inc. (CDXS) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 11:01 PM EDT - 1 year ago

Codexis, Inc. (CDXS) Q2 2024 Earnings Call Transcript


Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript

May 2, 2024, 8:24 PM EDT - 2 years ago

Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript


Codexis to Report First Quarter 2024 Financial Results on May 2

Apr 18, 2024, 4:05 PM EDT - 2 years ago

Codexis to Report First Quarter 2024 Financial Results on May 2


Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board

Apr 11, 2024, 7:05 AM EDT - 2 years ago

Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board


Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 10:39 PM EST - 2 years ago

Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript


Fingerlickengood
Fingerlickengood Mar. 21 at 4:11 AM
$CDXS Sometimes I wonder if they say things intentionally in their PRs to provide clues to whom they are working with, without directly breaching their contractional duties to not explicitly state it. $NVS "Codexis Inc., a provider of enzymatic solutions for therapeutics manufacturing, has entered into an agreement with an 'innovator pharmaceutical company' to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis .." No go look at Novartis home page, how many times do they use the word 'innovative/innovator/innovation'? https://www.novartis.com/research-and-development
1 · Reply
SnowyDingo
SnowyDingo Mar. 20 at 7:15 PM
$CDXS $QQQ please review this hidden gem
0 · Reply
Fingerlickengood
Fingerlickengood Mar. 20 at 3:49 PM
$CDXS $NVS $RNA And lines up nicely with an 'unnamed company' in their latest PR . "This agreement allows Codexis to supply siRNA material to support its partner’s preclinical program targeting a cardiovascular indication. Successfully delivering 50 grams marks an inflection point—more than tenfold typical research volumes—signaling Codexis’s capability to meet more demanding supply needs as RNA therapies expand into more prevalent diseases." Just saying ;) https://marketchameleon.com/articles/b/2026/3/5/codexis-agreement-50g-sirna-eco-synthesis-platform-expansion
1 · Reply
Fingerlickengood
Fingerlickengood Mar. 20 at 3:46 PM
0 · Reply
peepthestamp
peepthestamp Mar. 20 at 3:43 PM
$CDXS -Aging Well 👀
0 · Reply
Fingerlickengood
Fingerlickengood Mar. 20 at 3:42 PM
$CDXS $NVS $RNA Falls nicely in hand with their latest venture, Atrium Therapeutics and "will focus on precision RNA therapeutics for rare, genetic cardiomyopathies." https://www.pharmavoice.com/news/novartis-avidity-atrium-spinoff-rna-heart/815050/
1 · Reply
10xMoonstocks
10xMoonstocks Mar. 20 at 3:24 PM
$CDXS So much for shorts vacating. There is a ton of shares available currently. Every run has been countered by shorts bringing it back down....Just one contract announcement and they may disappear for a little while
0 · Reply
Michael2006
Michael2006 Mar. 20 at 1:50 PM
0 · Reply
nlstbro
nlstbro Mar. 20 at 1:46 PM
0 · Reply
nlstbro
nlstbro Mar. 20 at 1:46 PM
0 · Reply
Fingerlickengood
Fingerlickengood Mar. 20 at 4:05 AM
$CDXS we break $1.85 mananna!
0 · Reply
Fingerlickengood
Fingerlickengood Mar. 19 at 10:02 PM
$CDXS Controlled backout by the shorts happening on a daily basis, since the earnings were released last week! Clearly seen in the FINRA short volume ratio! GLTA. https://fintel.io/ss/us/cdxs
0 · Reply
Fingerlickengood
Fingerlickengood Mar. 19 at 9:26 PM
1 · Reply
Fingerlickengood
Fingerlickengood Mar. 19 at 9:25 PM
0 · Reply
nlstbro
nlstbro Mar. 19 at 7:28 PM
$CDXS Need to Maintain 1.63 +!
0 · Reply
buymoremakemore
buymoremakemore Mar. 19 at 5:04 PM
$CDXS Macro is horrible rn. Still impressed after a week how this is holding up
0 · Reply
CryptoDon93
CryptoDon93 Mar. 19 at 4:39 PM
$CDXS we expecting $1.75-2 any time soon?
3 · Reply
Fingerlickengood
Fingerlickengood Mar. 19 at 4:06 PM
$CDXS Where was Dr David Entwistle the past few days? (RNA Leaders Europe conference) and what was he presenting ?(Inclisiran scale up) Adds up very nicely!
2 · Reply
Fingerlickengood
Fingerlickengood Mar. 19 at 3:57 PM
$CDXS I've said this before and I will say it again, the only thing IMHO opinion for investing all this money into the ECO Synthesis GMP production facility they are building out in Hayward is if they have a 'very large potential contract' to manufacture on the line. What would that be? Inclisiran. It is currently solely produced in Europe by $NVS . What did Jimenez clearly say yesterday, "scale from 100 grams to 0.5 kilograms by year end...supported by successful quality inspections by a large pharmaceutical customer." That being said: "We expect to be in a position by middle of this year where we are not really exposed to tariffs, because we’re able to produce in the U.S. for the U.S. We have inventory on hand," Narasimhan told CNBC." https://www.investing.com/news/stock-market-news/novartis-ceo-says-company-likely-shielded-from-us-tariffs-93CH-4454980
0 · Reply
Fingerlickengood
Fingerlickengood Mar. 19 at 3:30 PM
1 · Reply
Fingerlickengood
Fingerlickengood Mar. 19 at 3:26 PM
$CDXS Laurence W. Lytton is an American investor and 10% owner of multiple public companies, often identified as a major stakeholder in micro-cap and small-cap stocks. The estimated net worth of Laurence W Lytton is at least $36 Million dollars as of 2026-03-14.
0 · Reply
Fingerlickengood
Fingerlickengood Mar. 19 at 2:57 PM
0 · Reply